Comparación de dos métodos de detección de posibles efectos adversos intrahospitalarios / No disponible

No disponible

[A study of the progression of the incidental prostate cancer depending on the kind of treatment performed]. / Estudio de la progresión del cáncer de próstata incidental según el tipo de tratamiento aplicado.

INTRODUCTION AND OBJECTIVES: Prostate cancer is a common neoplasm, with a significant burden of mortality. Since it's diagnosed at old ages and usually growths slowly, agresive treatment of localised cancer of prostate could be of little benefit. The study of the evolution of incidental prostate cancer diagnosed 20 years ago could give directions for present decision-making. METHODS: We performed a time survival analysis of patients diagnosed of incidental prostate cancer between 1980 and 2000, and followed them until april 2005. We analysed overall and disease-specific mortality, related to the kind of treatment and some anatomopathological characteristics. RESULTS: We included 80 cases. Treatment was hormonotherapy in 34 cases, surgery in 4, radiotherapy in 3 and watchful waiting in 39. Overall average survival was 8.87 years. Disease-specific survival in low risk group (Gleason lower than 6) was 16 years, and in high risk group (Gleason higher than 7) was 6 years. No differences were found between hormonotherapy and watchful waiting. CONCLUSIONS: While in low risk patients watchful waiting represents an acceptable aproaching, it could not be adequate in high risk cases. Hormonotherapy showed no benefit in incidental prostate cancer.

Estudio de la progresión del cáncer de próstata incidental según el tipo de tratamiento aplicado / A study of the progression of the incidental prostate cancer depending on the kind of treatment performed

Introducción y objetivos: El cáncer de próstata es una neoplasia frecuente y con una carga de mortalidad significativa. Dado que se diagnostica a edades avanzadas y que con frecuencia crece lentamente, el tratamiento agresivo del cáncer de próstata localizado podría, en algunos casos, no aportar grandes beneficios. El estudio de la evolución de los cánceres de próstata incidentales diagnosticados hace 20 años podrían servir de utilidad para guiar las decisiones actuales. Métodos: Análisis de supervivencia de los pacientes diagnosticados de cáncer de próstata incidental entre 1980 y 2000, con un seguimiento hasta abril de 2005. Se analizó la supervivencia global y la 'cáncer específica', según el tipo de tratamiento y diversos factores anatomopatológicos. Resultados: Se incluyeron 80 casos. De ellos, 34 fueron tratados con hormonoterapia, 4 con cirugía, 3 con radioterapia y 39 siguieron abstención vigilada. La supervivencia media fue de 8,87 años. En el grupo de bajo riesgo (Gleason menor de 6) la supervivencia cáncer-específica fue de 16 años y en el de alto riesgo (Gleason mayor de 7) de 6 años, sin diferencias por tratamiento. Conclusiones: En el grupo de bajo riesgo la abstención vigilada resulta una alternativa aceptable. Esta alternativa puede no ser válida en los de alto riesgo. La hormonoterapia no parece aportar beneficio alguno en los cánceres de próstata incidentales

Introduction and objectives: Prostate cancer is a common neoplasm, with a significant burden of mortality. Since it’s diagnosed at old ages and usually growths slowly, agresive treatment of localised cancer of prostate could be of little benefit. The study of the evolution of incidental prostate cancer diagnosed 20 years ago could give directions for present decision-making Methods: We performed a time survival analysis of patients diagnosed of incidental prostate cancer between 1980 and 2000, and followed them until april 2005. We analysed overall and disease-specific mortality, related to the kind of treatment and some anatomopathological characteristics. Results: We included 80 cases. Treatment was hormonotherapy in 34 cases, surgery in 4, radiotherapy in 3 and watchful waiting in 39. Overall average survival was 8.87 years. Disease-specific survival in low risk group (Gleason lower than 6) was 16 years, and in high risk group (Gleason higher than 7) was 6 years. No differences were found between hormonotherapy and watchful waiting. Conclusions: While in low risk patients watchful waiting represents an acceptable aproaching, it could not be adequate in high risk cases. Hormonotherapy showed no benefit in incidental prostate cancer